Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:

NCT ID: NCT05961007 Suspended - Clinical trials for Diabetic Macular Edema

Evaluation of IBI302 Injection in nAMD or DME

Start date: November 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.

NCT ID: NCT05953012 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

Start date: July 20, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).

NCT ID: NCT05941715 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

FAN
Start date: July 4, 2023
Phase: Phase 4
Study type: Interventional

Study purpose: To evaluate if previously high-frequent (3-5 weekly) aflibercept treated neovascular age-related macular degeneration (nAMD) can be extended in their treatment interval when switched to faricimab. Primary objective: To assess the efficacy of faricimab compared to aflibercept in terms of durability at 32 weeks by extending treatment interval in previous high-frequent aflibercept treated nAMD.

NCT ID: NCT05919693 Recruiting - Clinical trials for Diabetic Macular Edema (DME)

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

AMARONE
Start date: June 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of EYE103 will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

NCT ID: NCT05904691 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration (nAMD)

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Start date: November 1, 2023
Phase: Phase 1
Study type: Interventional

Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD

NCT ID: NCT05891548 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

ODYSSEY
Start date: May 31, 2023
Phase: Phase 2
Study type: Interventional

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in participants with neovascular age-related macular degeneration previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) standard of care therapy. Only one eye will be chosen as the study eye.

NCT ID: NCT05859776 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

DISCOVER
Start date: December 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question[s] it aims to answer are: - Safety of the maximum tolerable dose of AXT107 - Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.

NCT ID: NCT05831007 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)

Start date: December 6, 2021
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the safety and efficacy of LX102-C01 treatment of nAMD. This study will enroll subjects aged ≥ 50 years old to receive a single unilateral intravitreal (IVT) injection of LX102-C01 to evaluate its safety and efficacy.

NCT ID: NCT05769153 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration (nAMD)

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NOVA-1
Start date: December 6, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).

NCT ID: NCT05698329 Recruiting - Clinical trials for Diabetic Macular Edema

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).